立体定向放射外科治疗直接接触视路脑膜瘤的临床与影像学结局:国际多中心研究
该国际多中心回顾性研究纳入11家机构328例直接接触前视路脑膜瘤患者,中位随访56个月。93%接受单次SRS,64.6%为首选治疗。302例可评估视力者中9.6%出现视力下降,5.6%与肿瘤进展无关;322例影像随访中91.3%肿瘤稳定或缩小。SRS对经选择的围视路脑膜瘤相对安全。
要点
- 直接接触视路的脑膜瘤行SRS后,91.3%的患者在末次随访时影像学稳定或缩小。
- 可评估视力患者中9.6%出现视力下降,其中5.6%与肿瘤进展无关。
- SRS前KPS与视力下降独立相关(校正OR 0.9,95%CI 0.9-1.0,p<0.01)。
核心结论
- 多数直接接触前视路的脑膜瘤患者经SRS后实现肿瘤控制并保留视力功能。
- SRS对经选择的围视路脑膜瘤患者是相对安全的治疗方式。
研究设计与样本
- 国际多中心回顾性分析,纳入11家机构共328例直接接触视路的脑膜瘤患者。
- SRS后中位随访56个月,随访时行神经系统检查含视力评估,并系列MR评估肿瘤体积。
- 采用单变量和多变量logistic回归识别视力缺陷的预测因素。
主要发现
- 64.6%的患者以SRS为首选治疗,93%接受单次SRS。
- 302例有视力信息的患者中29例(9.6%)出现视力下降,其中12例(41.4%)有肿瘤进展证据。
- 其余17例(5.6%)视力下降与肿瘤进展无关。
- 校正分析中,SRS前KPS预测视力下降(校正OR 0.9,95%CI 0.9-1.0,p<0.01)。
- 322例有影像随访的患者中294例(91.3%)末次随访时影像学稳定或肿瘤缩小;症状持续时间与肿瘤进展相关(校正OR 1.01,校正95%CI 1.0-1.02,校正p=0.02)。
临床怎么用
- 对经选择的直接接触视路脑膜瘤患者,可考虑SRS作为微创治疗选择。
- 治疗前评估KPS有助于识别视力下降风险较高的患者。
- SRS后需系列MR和视力评估以监测肿瘤控制与视觉功能。
局限性
- 本研究为回顾性多中心分析,未报告随机对照或前瞻性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Resection of meningiomas in direct contact with the anterior optic apparatus carries risk of injury to the visual pathway. Stereotactic radiosurgery (SRS) offers a minimally invasive alternative. However, its use is limited owing to the risk of radiation-induced optic neuropathy. Few SRS studies have specifically assessed the risks and benefits of treating meningiomas in direct contact with the optic nerve, chiasm, or optic tract. The authors hypothesized that SRS is safe for select patients with meningiomas in direct contact with the anterior optic apparatus. METHODS: The authors performed an international multicenter retrospective analysis of 328 patients across 11 institutions. All patients had meningiomas in direct contract with the optic apparatus. Patients were followed for a median duration of 56 months after SRS. Neurological examinations, including visual function evaluations, were performed at follow-up visits. Clinical and treatment variables were collected at each site according to protocol. Tumor volumes were assessed with serial MR imaging. Variables predictive of visual deficit were identified using univariable and multivariable logistic regression. RESULTS: SRS was the initial treatment modality for 64.6% of patients, and 93% of patients received SRS as a single fraction. Visual information was available for 302 patients. Of these patients, visual decline occurred in 29 patients (9.6%), of whom 12 (41.4%) had evidence of tumor progression. Visual decline in the remaining 17 patients (5.6%) was not associated with tumor progression. Pre-SRS Karnofsky Performance Status predicted visual decline in adjusted analysis (adjusted OR 0.9, 95% CI 0.9-1.0, p < 0.01). Follow-up imaging data were available for 322 patients. Of these patients, 294 patients (91.3%) had radiographic evidence of stability or tumor regression at last follow up. Symptom duration was associated with tumor progression in adjusted analysis (adjusted OR 1.01, adjusted 95% CI 1.0-1.02, adjusted p = 0.02). CONCLUSIONS: In this international multicenter study, the vast majority of patients exhibited tumor control and preservation of visual function when SRS was used to treat meningioma in direct contact with the anterior optic pathways. SRS is a relatively safe treatment modality for select patients with perioptic meningiomas in direct contact with the optic apparatus.
引用
- Asuzu DT, Bunevicius A, Kormath Anand R, et al. Clinical and radiologic outcomes after stereotactic radiosurgery for meningiomas in direct contact with the optic apparatus: an international multicenter study. J Neurosurg. 2021. PMID: 34560648. doi:10.3171/2021.3.JNS21328
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。